rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Fulcrum Therapeutics, Inc.

FULC · Nasdaq

Health CareBiotechnologyNot moving yet

FULC stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 34 weeks. It is 26.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 34
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$3.0M
Insider sales, 12 months
$59.7M
Officials’ trades on record
0
Institutions holding
148 (-13)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$56.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months7
Buyers · sellers2 · 4
WhoDidSharesTraded
Kevin Tang10% ownerbought50,945at $3.5217 Jul 2026filed 20 Jul 2026
Kevin Tang10% ownerbought116,671at $3.5616 Jul 2026filed 20 Jul 2026
Kevin Tang10% ownerbought107,377at $3.5615 Jul 2026filed 15 Jul 2026
Kevin Tang10% ownerbought53,651at $3.5614 Jul 2026filed 15 Jul 2026
Kevin Tang10% ownerbought75,952at $3.5814 Jul 2026filed 15 Jul 2026
Kevin Tang10% ownerbought12,966at $3.5413 Jul 2026filed 15 Jul 2026
Alan EzekowitzDirectorsold18,000at $3.6526 Jun 2026filed 30 Jun 2026
Robert J. GouldDirectorsold15,000at $10.722 Feb 2026filed 4 Feb 2026
Robert J. GouldDirectorsold15,000at $11.872 Jan 2026filed 6 Jan 2026
Robert J. GouldDirectorsold15,000at $10.872 Jan 2026filed 4 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders148-13 on the quarter
New · exited29 · 43
Reported value$287.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20268,824,259$32.3M+3,433,666+63.7%
EcoR1 Capital, LLCnew · filed 14 Aug 20266,549,866$24.0M+6,549,866
TANG CAPITAL MANAGEMENT LLCnew · filed 14 Aug 20266,521,412$23.9M+6,521,412
Nantahala Capital Management, LLCadded · filed 14 Aug 20265,475,040$20.0M+2,425,000+79.5%
MONTANOVA CAPITAL, LLCreduced · filed 14 Aug 20263,680,921$13.5M-2,880,190−43.9%
D. E. Shaw & Co., Inc.added · filed 14 Aug 20263,044,385$11.1M+1,421,104+87.5%
CITADEL ADVISORS LLCadded · filed 14 Aug 20262,704,505$9.9M+1,412,019+109.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,697,216$9.9M+4,268+0.2%
JANE STREET GROUP, LLCadded · filed 14 Aug 20262,217,498$8.1M+1,907,081+614.4%
STATE STREET CORPadded · filed 7 Aug 20262,037,025$7.5M+487,174+31.4%
31 Mar 2023 – 30 Jun 2026
73116159Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Kevin Tang Company insider10% owner · last 17 Jul 20265 · 0
Tang Capital Management Llc Company insider10% owner · last 15 Jul 20263 · 0
Alan Ezekowitz Company insiderDirector · last 30 Jun 20260 · 1
Colin Hill Company insiderDirector · last 30 Jun 20260 · 0
James A. Geraghty Company insiderDirector · last 30 Jun 20261 · 0
Kate Haviland Company insiderDirector · last 30 Jun 20260 · 0
Katina Dorton Company insiderDirector · last 30 Jun 20260 · 0
Rachel K. King Company insiderDirector · last 30 Jun 20260 · 0
Robert J. Gould Company insiderDirector · last 30 Jun 20260 · 29
Sonja Banks Company insiderDirector · last 30 Jun 20260 · 0
Joshua Lehrer-Graiwer Company insiderDirector · last 23 Apr 20260 · 0
Alan A. Musso Company insiderChief Financial Officer · last 2 Feb 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-24.0%
Share count trendFY 2025 · to 17 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$197.5M
Free cash flowFY 2025 · to 31 Dec 2025−$60.4M

Analyst forecasts

No analyst forecasts yet.